Tiragolumab: tested in a combination
28 studies: another drug in the study is under test too. Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3How we knowReport a problem
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)RecruitingNCT04929223Phase 1How we knowReport a problem
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2How we knowReport a problem
- A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular CarcinomaTerminatedNCT05908786Phase 1/2Results postedHow we knowReport a problem
- An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaTerminatedNCT05315713Phase 1/2Results postedHow we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedNCT05116202Phase 1/2Results postedHow we knowReport a problem
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedNCT04632992Phase 2Results postedHow we knowReport a problem
- A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical CancerCompletedNCT04300647Phase 2Results postedHow we knowReport a problem
- Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 InhibitorCompletedNCT03977467Phase 2Results postedHow we knowReport a problem
- Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)TerminatedNCT03869190Phase 1/2Results postedHow we knowReport a problem
- Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedNCT03554083Phase 2Results postedHow we knowReport a problem
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results postedHow we knowReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)TerminatedNCT03281369Phase 1/2Results postedHow we knowReport a problem
- A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)CompletedNCT03193190Phase 1/2Results postedHow we knowReport a problem
- STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1WithdrawnNCT07038915Phase 2How we knowReport a problem
- Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal CancerActive, not recruitingNCT06784947Phase 2How we knowReport a problem
- A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)WithdrawnNCT06331598Phase 2How we knowReport a problem
- Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2How we knowReport a problem
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell CarcinomaCompletedNCT05805501Phase 2How we knowReport a problem
- Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingNCT05798663Phase 2How we knowReport a problem
- Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)CompletedNCT05661188Phase 2How we knowReport a problem
- A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial CancerActive, not recruitingNCT05645692Phase 2How we knowReport a problem
- Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingNCT05394337Phase 1/2How we knowReport a problem
- A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Phase 3How we knowReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2How we knowReport a problem
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1How we knowReport a problem
- Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaActive, not recruitingNCT03784326Phase 2How we knowReport a problem
- Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT03708224Phase 2How we knowReport a problem